The scale of the underlying problem is sobering. According to the World Health Organization, cancer is the second leading cause of death globally, with roughly 20 million new cases diagnosed in 2022, a figure expected to climb in the coming years. Pediatric cancers, though representing about one percent of global diagnoses, are also rising, with an estimated 13.7 million new cases of childhood cancer projected between 2020 and 2050. Each of those diagnoses ripples outward to parents, siblings, partners, and friends, many of whom take on informal caregiving roles with little psychological support of their own.

Receiving a potentially life-threatening diagnosis can trigger significant psychological and cognitive challenges that touch nearly every domain of personal life. If left unaddressed, this burden can erode well-being and quality of life, and can even undermine adherence to treatment itself. Psychological distress shapes how clearly patients think, how confident they feel in managing their illness, how they communicate with clinicians, how they perceive risk, and ultimately how they make some of the most consequential decisions of their lives. In other words, mental health is not a luxury add-on to cancer care; it is woven into the machinery of treatment outcomes.

Psycho-oncological interventions, when they are available, can support people of all ages, foster adherence to clinical recommendations, and help surface patients’ preferences and needs throughout the care pathway. Clinical practice guidelines already recommend psychological assessment not only at diagnosis but at multiple phases of the illness, because emotional and cognitive burden shifts over time and varies with psychological factors and age. The problem is delivery. Access to psycho-oncological support is limited across healthcare systems for structural reasons, including resource constraints and the insufficient integration of psychological care into routine oncological pathways. Individual-level barriers compound the problem: low awareness of available services, stigma, shame, perceived discrimination, and wide heterogeneity in patients’ perceived needs and help-seeking attitudes.

There is also a blind spot in the guidelines themselves. Most clinical practice guidelines focus primarily on adult populations, with comparatively limited attention to pediatric patients and informal caregivers, precisely the groups whose psychological needs can be most easily overlooked. It is against this backdrop that the ALTHEA project, whose full name expands to tAckling menTal Health cancer patients and their families: digital solutions for bEtter cAre, has taken shape. Co-funded by the European Union’s EU4Health Programme under grant agreement number 101161236, the project brings together an unusually broad coalition: oncologists, health psychologists, neuropsychologists, pediatric cancer specialists, nursing scientists, computer scientists, patient advocacy organizations, and European cancer policy bodies spanning countries from Italy and Germany to Ukraine, Lithuania, Cyprus, and beyond.

The centerpiece of the project is a novel web-based digital platform designed to serve both cancer patients and their informal caregivers across different stages of the care pathway, and to be available to healthcare professionals as well. The platform’s architecture rests on three integrated functions. The first is psychological and cognitive assessment: a unique testing battery will be developed for both pediatric and adult patients and informal caregivers, drawing on clinical practice guidelines, care guidelines, and existing validated tests and self-reported measures. The second function is support profile identification, and the third is the delivery of tailored psychological support and educational material, including resources that equip healthcare professionals to navigate mental health issues in oncology and to refer patients to specialized psycho-oncologists and neuropsychologists when needed.

The support profile system is where the platform’s technical ambition becomes most visible. Based on the results of the psychological and cognitive assessments, and taking into account what the consortium calls complexity indicators, psychosocial vulnerability factors that sharpen the specificity of the final classification, each user is assigned to one of four profiles corresponding to progressively higher levels of intervention intensity. Profile 0 users are invited to follow-up and ongoing reassessment through the screening module, so that early changes in psychosocial status can be detected. Profile 1 users receive general educational materials, self-help content, and digital interventions designed to support psychological adjustment and promote adaptive coping strategies, alongside continued reassessment. Profile 2 users receive self-help content, tailored educational materials, digital interventions, and guided professional support delivered through the platform by psycho-oncologists, health psychologists, and neuropsychologists, targeting issues such as emotional distress, sleep quality, and cognitive functioning in line with clinical best practice. Profile 3 users, those with the most complex needs, are referred to specialized care with personalized recommendations for integrated support, ensuring timely access to appropriate specialists.

What distinguishes ALTHEA from existing digital health platforms, its developers argue, is the combination of screening, classification into support profiles, and tailored interventions within a single platform, together with a co-creation approach that actively involves patients, caregivers, and healthcare professionals in its design. The development process will be grounded in the scientific literature and in data collected directly from end-users, an attempt to ensure the platform reflects real needs rather than assumptions about them. The consortium is also explicit about the risks. Digital solutions can overcome traditional barriers to access, but they can also generate new forms of inequality, for instance through uneven accessibility among countries. Some people, particularly older adults with lower levels of digital literacy, may be less inclined to engage with an online platform at all, and building a tool for heterogeneous populations requires the inclusion of a wide range of participant groups throughout the process to ensure the validity of its contents.

To counteract these risks, the authors outline a set of design and implementation strategies: inclusive design, multilingual interfaces, culturally adapted content, and careful prioritization of resources. Features such as gamification, easily accessible content, and low-bandwidth solutions may further enhance the platform’s ability to deliver tailored interventions and sustain user engagement across diverse populations. Crucially, the project treats people with lived experience of cancer not merely as study participants but as co-creators and advisors, an approach the consortium says enhances the platform’s relevance, usability, acceptability, and ethical foundation. Algorithm-based approaches to matching patients with support levels are described as promising, though the authors are candid that further empirical validation is needed to establish their effectiveness and generalisability.

If it delivers on its promise, the consortium argues, ALTHEA could contribute to more accessible and integrated psycho-oncological care by easing the incorporation of psychological support into routine clinical pathways, supporting early identification of psychological needs through structured screening, and improving access to tailored interventions across diverse populations. It may also inform more standardized approaches to mental health assessment in oncology and help build more equitable, scalable models of care. For now, the team is careful about what remains to be proven: future research will be essential to evaluate the platform’s clinical effectiveness, scalability, implementation in real-world settings, and its impact on clinical outcomes. But in a field where millions of patients and families navigate cancer’s psychological toll with inadequate support, the ambition of a single platform that screens, classifies, and responds to mental health needs across the entire cancer journey represents a significant step toward making the mind an equal partner with the body in cancer care.

Subject of Research: A digital mental health platform for cancer patients and their families

Article Title: Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project

Article References: Durosini, I., Monzani, D., Coppini, V., Ferrari, M. V., Bovolenta, C., Grigis, A., Curigliano, G., Zagami, P., Munzone, E., Minchella, I., Magnoni, F., Peccatori, F. A., Scholl, I., Meyerheim, M., Van Hemelrijck, M., Gsell, H., Gosak, L., Ciria-Suarez, L., Làvo, K., … the ALTHEA Consortium (2026). Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project. PLOS Digital Health, 5(10), e0001675. https://doi.org/10.1371/journal.pdig.0001675

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001675

Keywords: digital health, psycho-oncology, cancer care, mental health screening, caregivers, ALTHEA project, EU4Health, clinical guidelines, patient empowerment, co-creation, telemedicine, healthcare inequality

The European Cardiovascular Health Data and AI Network, known as CHAIN, has been launched with €20 million in funding from the EU4Health Programme and is coordinated by the European Society of Cardiology (ESC). The 36-month project brings together a consortium of 53 partners from 20 European countries, spanning universities and research centres, hospitals and clinical networks, technology companies, national ministries of health and patient organisations. Its central ambition is to build a federated ecosystem for the safe, effective and scalable adoption of AI in cardiovascular care, aligned with the European Health Data Space, the EU’s ambitious framework for cross-border health data sharing.

The problem CHAIN seeks to solve is well documented. AI models capable of detecting heart disease earlier, stratifying patient risk more accurately and supporting clinical decisions have proliferated in the scientific literature, yet their uptake in routine care remains patchy and inconsistent. Standardised validation mechanisms are largely lacking, meaning hospitals and health authorities often have no reliable way of knowing which algorithms perform as advertised, for which patient populations, and under which clinical conditions. The result is a landscape in which promising tools stall at the pilot stage while unvetted ones occasionally reach clinics without adequate scrutiny.

CHAIN’s technical answer to this challenge rests on two pillars: a federated data infrastructure and a system of validation credentials. Rather than centralising sensitive patient records, the project will securely connect hospitals, health data hubs and disease registries across Europe in a federated architecture, allowing AI solutions to be tested, validated and deployed at scale while data remain within their originating institutions. This approach, which aligns with the privacy-preserving principles underpinning the European Health Data Space, enables algorithms to be evaluated on diverse, real-world populations drawn from multiple healthcare systems, a critical step for detecting the biases and performance gaps that often emerge when models trained in one setting are applied in another.

The second pillar is a European repository of validated AI solutions, each accompanied by what the project calls an ‘AI passport’. These passports will document a model’s performance, safety and suitability for clinical use, giving healthcare authorities, hospital administrators and practicing clinicians clear, standardised evidence on which solutions work, for whom and in which settings. In an era when clinicians and patients alike are wary of opaque algorithmic tools, the passports are designed to function as a trusted seal of approval, helping decision-makers distinguish genuinely useful innovations from overhyped ones. Professor Folkert Asselbergs of Amsterdam University Medical Centre, CHAIN’s scientific coordinator and chair of the ESC AI Gateway, emphasised that in an era of misinformation, patients and healthcare professionals are looking to medical societies to provide a framework for implementing trusted solutions that add real value beyond what is currently available.

To prove the framework works in practice, CHAIN will implement six real-world use cases across 13 countries, deliberately chosen to cover the full continuum of cardiovascular care. The use cases span risk stratification, early disease detection, clinical decision support and the management of complex cardiovascular conditions, ensuring that the validation and deployment mechanisms are tested across different healthcare settings, from large academic centres to smaller regional hospitals. This breadth matters: an AI tool that performs well in a well-resourced Dutch university hospital may fail in a rural clinic in eastern Europe, and the project’s multi-country design is intended to surface such disparities before tools are scaled.

The initiative does not start from scratch. CHAIN builds on the ESC’s EuroHeart registry network, which already unifies 18 ESC member countries with standardised data on cardiovascular care and outcomes, providing tools that help countries monitor results, compare practices and drive sustainable improvements. It will also seek synergies with a constellation of existing EU projects, including EUCAIM, COMPASS AI, AI4HF, DataTools4Heart, EHDEN, JACARDI, TEHDAS2 and Xt-EHR, an effort to maximise complementarities and avoid duplicating infrastructure that Europe has already invested in. The project is explicitly positioned as a key implementation vehicle for the EU Safe Hearts Plan, in particular its flagship initiative on innovation and integration of AI and digital technologies in cardiovascular healthcare.

Timing is a central theme of the launch. CHAIN arrives just as the European Health Data Space, the EU’s landmark AI Act, and an evolving regulatory framework for medical products, spanning pharmaceutical, medical device and in vitro diagnostic legislation, are reshaping how AI is developed, evaluated and deployed across European healthcare. Navigating this regulatory landscape is one of the project’s implicit challenges: any AI tool validated through CHAIN will need to satisfy not only clinical evidence standards but also the transparency, safety and human-oversight requirements that the AI Act imposes on high-risk medical applications. By building governance, evaluation and scale-up mechanisms into its core design, the consortium hopes to create a template that regulators, industry and health systems can adopt more widely.

The political weight behind the project is considerable. Olivér Várhelyi, the EU Commissioner for Health and Animal Welfare, framed the challenge bluntly, saying the question is no longer simply what AI can do, but how to make it work safely and effectively for patients and health professionals in everyday healthcare, and that this is where CHAIN can make a real difference. Professor Cecilia Linde, President of the ESC and a cardiologist at the Karolinska Institute in Sweden, struck a similar note, arguing that the need to act is critical given that one in three deaths in Europe is caused by cardiovascular disease, and describing CHAIN as an effort to turn the promise of AI into better cardiovascular health for everyone by helping trusted innovations reach patients safely and equitably.

Over the next three years, the consortium hopes to deliver a strategic roadmap for scaling AI adoption in cardiology across Europe, one that Professor Asselbergs says will benefit research and industry through shared infrastructure and standards, while validated decision-support tools help reduce the burden on overstretched healthcare systems. The ultimate measure of success, he argues, will be clinical: trustworthy tools that translate into earlier, more accurate diagnosis and safer, more personalised care for patients. If CHAIN succeeds, it could offer something Europe has lacked so far, a coherent, continent-scale pathway for moving AI in medicine from promising publications to measurable patient impact, and a model that other fields of medicine, from oncology to neurology, may soon seek to replicate.

Subject of Research: A European initiative to validate and scale artificial intelligence for cardiovascular disease prevention, detection and treatment

Article Title: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care

Article References: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, cardiovascular disease, CHAIN, European Society of Cardiology, EU4Health, European Health Data Space, AI validation, federated data, clinical decision support, health data infrastructure, AI passports, digital health

The study, conducted by Antonio Puertas Gallardo and Magdalena Stepien of the European Commission’s Joint Research Centre in Ispra, Italy, together with Antonino Brunetto of ARHS Developments Italia in Milan, examined 102 projects funded under Horizon Europe, the EU4Health programme, and the Digital Europe Programme. Together, these initiatives represent a combined investment of more than 840 million euros dedicated to understanding, detecting, treating and preventing cancer. The work is significant not merely for its headline figures but for its methodology, which demonstrates how modern artificial intelligence tools can bring order to the sprawling, fragmented record of publicly funded research.

The researchers employed a combination of quantitative and qualitative methods to characterise the funding landscape and identify patterns within it. The centrepiece of their approach was the application of large language model methodology to assign standardised keywords to each project in the portfolio. This was no trivial task. EU-funded cancer projects span an enormous range of activities, from laboratory-based investigations of tumour biology to public health campaigns and the construction of digital infrastructure for sharing clinical data. Without a common vocabulary, comparing projects across different programmes and directorates-general becomes nearly impossible, and opportunities for synergy go unnoticed.

By using large language models to read and classify project descriptions, the team developed a set of 56 standardised keywords capable of clustering the 102 projects into coherent thematic groups. This keyword framework allowed the researchers to identify synergies and thematic interconnections among cancer-related initiatives that would otherwise remain buried in separate databases and reporting formats. The most frequent terms to emerge from this analysis related to healthcare, policy and guidance, and digital aspects, reflecting the fact that EU cancer funding is not confined to the bench but extends deep into health systems, regulation and technology.

The thematic findings offer a revealing snapshot of European priorities. Most of the funded projects concentrated on diagnosis, treatment and prevention, the three pillars of clinical oncology. When the analysis turned to specific cancer types, colorectal and breast cancers emerged as the most common areas of focus, a pattern consistent with their status as two of the most frequently diagnosed malignancies in Europe and with the existence of dedicated screening programmes across many member states. The prominence of digital keywords underscores how thoroughly data science, artificial intelligence and e-health technologies have penetrated the cancer research agenda, from computational pathology platforms to federated networks for sharing sensitive patient information.

Equally striking were the geographic patterns the analysis uncovered. Institutions from larger western and southern European countries proved to be the most active participants in EU cancer funding, dominating both the coordination of projects and participation more broadly. Distinct collaboration networks between specific institutions were identified, revealing clusters of organisations that repeatedly join forces across successive funding calls. These networks represent a form of institutional capital that is invisible in simple funding statistics but crucial to understanding how European research capacity is actually organised and reproduced over time.

Perhaps the most politically consequential finding concerns the relationship between national characteristics and funding success. The study found that countries with larger populations were involved in a greater number of projects, but that countries with a higher gross domestic product per capita were not. In other words, wealth per citizen does not predict engagement with EU cancer funding, but sheer demographic weight does. This distinction matters for ongoing debates about the equity of EU research funding. Smaller member states have long voiced concerns that framework programmes disproportionately reward large, well-established research systems, and this analysis provides granular evidence with which such concerns can now be assessed and, potentially, addressed through targeted policy interventions.

The technical achievement underlying these findings deserves attention in its own right. Assigning standardised keywords to research projects has traditionally been a labour-intensive exercise requiring expert panels to read and code hundreds of project abstracts, a process that is slow, expensive and difficult to reproduce. Large language models, by contrast, can process project descriptions at scale and apply a consistent classification scheme, making it feasible to update the mapping continuously as new projects are funded. The authors’ use of this technology within an official Commission analysis signals a broader shift in how public administrations may approach evidence-based policymaking, treating the text of research proposals and reports not as administrative residue but as analysable data.

The practical implications extend beyond academic interest. The European Commission’s cancer projects tool, which provided the data for this study, is designed to give policymakers, researchers and the public a transparent view of EU cancer funding. By demonstrating how the tool’s contents can be systematically analysed, the authors have laid what they describe as the foundation for more strategic planning of EU cancer funding. Identifying thematic clusters makes it possible to spot both overcrowded areas, where additional investment may yield diminishing returns, and neglected ones, where gaps in the portfolio may warrant attention in future work programmes. Mapping collaboration networks similarly allows funders to see which institutions are consistently included and which remain on the margins of European cancer research.

The study arrives at a moment when Europe’s ambition to reduce the cancer burden is codified in policy initiatives spanning research, health systems and digital infrastructure. What this analysis makes clear is that ambition is backed by substantial and traceable resources: more than 840 million euros distributed across 102 projects spanning three complementary programmes. What it also makes clear is that the distribution of those resources follows identifiable structural patterns, shaped by population size, institutional networks and thematic fashion. By making those patterns visible, the Joint Research Centre team has transformed a collection of individual project records into a strategic instrument, one that could help ensure that the next generation of European cancer funding is planned not by habit or accident, but by design.

Subject of Research: Analysis of European Union cancer research funding across Horizon Europe, EU4Health and the Digital Europe Programme

Article Title: Unveiling European cancer funding: insights from the European Commission’s cancer projects tool

Article References: Puertas Gallardo, A., Brunetto, A., & Stepien, M. (2026). Unveiling European cancer funding: insights from the European Commission’s cancer projects tool. Health Research Policy and Systems. https://doi.org/10.1186/s12961-026-01535-9

Image Credits: AI Generated

DOI: 10.1186/s12961-026-01535-9

Keywords: cancer funding, Horizon Europe, EU4Health, Digital Europe Programme, large language models, European Commission, Joint Research Centre, cancer policy, research collaboration, colorectal cancer, breast cancer, health research policy